Publication Name	World Journal of Gastroenterology
Manuscript ID	111282
Country	Greece

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Cohort Study
Article Title	Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study
Manuscript Source	Invited Manuscript
All Author List	Maria Tzouvala, Eirini Zacharopoulou, Maria Kalafateli, Nikos Viazis, Andreas Psistakis, Angeliki Theodoropoulou, Ioannis Drygiannakis, Konstantinos Karmiris, Ioannis E Koutroubakis, Polyxeni Kevrekidou, Kostas Soufleris, Marios Katsaros, Olga Giouleme, Fotios Fousekis, Konstantinos Katsanos, Dimitrios Christodoulou, Aikaterini Gaki, Evgenia Papathanasiou, Giorgos Bamias, Evanthia Zampeli, Spyridon Michopoulos, Nikolaos Kyriakos, Christos Veretanos, Konstantinos Argyriou, Andreas Kapsoritakis, George Tribonias, Gerassimos J Mantzaris and Christos Liatsos
Funding Agency and Grant Number
Corresponding Author	Christos Liatsos, Director, MD, PhD, Department of Gastroenterology, 401 General Military Hospital of Athens, Panagioti Kanellopoulou Ave, Athens 11525, Greece. cliatsos@yahoo.com
Key Words	Ulcerative colitis; Tofacitinib; Extended induction; Predictors; Efficacy; Safety; Real-world study
Core Tip	This multicenter, retrospective cohort study evaluated the effectiveness and safety of administering a 16-week extended induction protocol for tofacitinib in patients with moderate-to-severe ulcerative colitis. At week 52 over half of the patients achieved clinical remission with a drug persistence rate of 75.7%. Notably, prior exposure to biologics was associated with the need for continuous administration of escalated doses while active smoking was significantly associated with treatment discontinuation. Extended induction therapy in selected patients may be beneficial. Our study highlights the need for further research to identify predictors of long-term response and optimal dosing strategies.
Citation	Tzouvala M, Zacharopoulou E, Kalafateli M, Viazis N, Psistakis A, Theodoropoulou A, Drygiannakis I, Karmiris K, Koutroubakis IE, Kevrekidou P, Soufleris K, Katsaros M, Giouleme O, Fousekis F, Katsanos K, Christodoulou D, Gaki A, Papathanasiou E, Bamias G, Zampeli E, Michopoulos S, Kyriakos N, Veretanos C, Argyriou K, Kapsoritakis A, Tribonias G, Mantzaris GJ, Liatsos C. Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study. World J Gastroenterol 2025; In press

Received	2025-07-01 03:44
Peer-Review Started	2025-07-01 03:44
To Make the First Decision
Return for Revision	2025-08-01 09:57
Revised	2025-08-13 20:08
Second Decision	2025-10-13 02:50
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-10-13 07:58
Articles in Press	2025-10-13 07:58
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com